Use access key #2 to skip to page content.
$12.30 -1.38 (-10.09%)
10/10/2008 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View All Commentary (AMLN)

Recs

0

Avatar mwehrman (< 20) Submitted: 3/01/07 1:52 PM : Outperform Start Price: $37.64 AMLN Score: -30.19

Drug approvals look good and they are targeting large markets - e.g. obesity, etc.

Report this Post Replies: 0 | Reply

Featured Broker Partners